Drug
S1 capsule
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Terminated(1)
Other(2)
Detailed Status
unknown2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
unknown267%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
withdrawnphase_1
SOX-based CRT for Esophageal Cancer.
NCT03991104
unknownphase_2
Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen
NCT04101929
unknownphase_2
Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection
NCT02223611
Clinical Trials (3)
Showing 3 of 3 trials
NCT03991104Phase 1
SOX-based CRT for Esophageal Cancer.
NCT04101929Phase 2
Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen
NCT02223611Phase 2
Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3